SCHEMBL19915935

SCHEMBL19915935

Bc1ccc2cncn2c1C(=O)OC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 7/20 0.39
ALDH1A1 P00352 3/20 0.38
KDM4E B2RXH2 2/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 1/20 0.38
HSD17B10 Q99714 1/20 0.38
MAPK1 P28482 1/20 0.35
TBXAS1 P24557 6/20 0.35
DAPK3 O43293 1/20 0.35
JAK2 O60674 1/20 0.35
PRKD3 O94806 1/20 0.35
MAP4K4 O95819 1/20 0.35
ABL1 P00519 1/20 0.35
CSF1R P07333 1/20 0.35
RET P07949 1/20 0.35
MET P08581 1/20 0.35
PDGFRA P16234 1/20 0.35
PRKACA P17612 1/20 0.35
LTK P29376 1/20 0.35
GRK5 P34947 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19915857 0.82 IDO1 (0.39) IDO1ALDH1A1KDM4EHPGDTSHR
SCHEMBL19915938 0.81 TBXAS1 (0.39) IDO1TBXAS1
SCHEMBL21060531 0.77 IDO1 (0.51) IDO1ALDH1A1KDM4EHPGDTSHR
SCHEMBL19915858 0.77 IDO1 (0.50) IDO1ALDH1A1MAPK1HTT
SCHEMBL1616007 0.74 KDM4E (0.48) IDO1ALDH1A1KDM4EHPGDTSHR
SCHEMBL28708782 0.73 ALDH1A1 (0.40) IDO1ALDH1A1KDM4EHPGDTSHR
SCHEMBL26693866 0.72 GAA (0.35) IDO1ALDH1A1KDM4EHSD17B10MAPK1
SCHEMBL28701542 0.71 TBXAS1 (0.35) IDO1ALDH1A1KDM4EHPGDTSHR
SCHEMBL19915958 0.70 TSHR (0.36) IDO1ALDH1A1KDM4ETSHRMAPK1
SCHEMBL28686852 0.70 KCNH2 (0.33) IDO1ALDH1A1KDM4EHPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018036414-A1 FUSED HETEROCYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 北京诺诚健华医药科技有限公司 2018-03-01 WO disclosed